PET-imaging of Two Vartumabs in Patients With Solid Tumors

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorVar2 Pharmaceuticals

About this trial

VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).

Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues.

VAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these as radiolabeled antibody fragments to study biodistribution, tumor accumulation, pharmacodynamics and clearance pathways in a diverse patient population.

Eligibility criteria

Qualifiers

Willing to adhere to the prohibitions and restrictions specified in this protocol.

Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study and is willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol.

Patients aged ≥ 18 years at moment of signing informed consent form.

Life expectancy of > 12 weeks.

Disqualifiers

Behavioral or cognitive impairment or psychiatric disease that, in the investigator's opinion, affects the patient's ability to understand and cooperate with the study protocol.

Insufficient venous access for the study procedures.

Close affiliation with the investigator, e.g. a close relative of the investigator, dependent person (e.g. employee or student), employee of the department of surgery or nuclear department of the UMCG,TRACER or affiliates.

Any finding in the medical examinations or medical history giving, in the opinion of the investigator, reasonable suspicion of a disease or condition that makes treatment with the investigational drug unadvisable, or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications.

Trial design

Treatments tested in this trial

  • 89Zr-DFO-N-Suc-F8scFv
  • 89Zr-DFO-N-Suc-C9scFv
  • PET/CT scan

Treatment groups

32 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Var2 Pharmaceuticals

Lead sponsor

TRACER Europe BV

Collaborator